The 13% Cost-Plus Myth? What Israeli Tax Ruling 5007/26 Really Says About R&D Center - Transfer Pri

 

Tax Ruling 5007/26: Has the Israeli Tax Authority Established a New 13% Cost-Plus Standard?

The ruling concerns an Israeli company providing research and development services to a foreign affiliated company within a multinational enterprise group.

Under the ruling, the Israeli Tax Authority approved a remuneration model based on a 13% Net Cost Plus return using the Transactional Net Margin Method (TNMM) and a Mark-Up on Total Costs (MTC) profit level indicator.

The ruling is particularly noteworthy because the Israeli Tax Authority did not require a residual profit split mechanism despite recent international discussions emphasizing DEMPE functions and the allocation of intellectual property-related returns.

However, perhaps the most important takeaway from the ruling is what it does not say.

The ruling does not state that every Israeli R&D center should earn a 13% markup. It does not establish a minimum acceptable return. Nor does it introduce a transfer pricing safe harbor applicable to Israeli technology companies.

Instead, the ruling reflects the Israeli Tax Authority's acceptance of a specific transfer pricing outcome based on a specific fact pattern.
 

The Facts Behind the Approved 13% Return

According to the published ruling, the following characteristics played a significant role in the Israeli Tax Authority's analysis:

• The foreign company is the ultimate parent company of a large multinational group generating more than USD 10 billion in annual revenue.
• Senior management and the board of directors operate outside Israel.
• The foreign company funds the R&D activities.
• The foreign company controls and assumes the principal R&D risks.
• The foreign company owns the relevant intellectual property.
• The Israeli company operates as one of several R&D centers globally.
• Strategic decisions relating to intellectual property development are made outside Israel.
• No group-level senior executives are employed by the Israeli entity.
• The Israeli company performs limited-risk R&D services.

These facts are not incidental. They appear to have been central to the approval granted under the ruling.
 

Does Every Israeli R&D Center Need a 13% Net Cost Plus Return?

The answer is clearly no.

Although the ruling approved a 13% markup, it does not suggest that 13% represents a universal arm's-length outcome for all Israeli R&D centers.

Transfer pricing remains fundamentally fact-driven.

Where a taxpayer prepares a robust transfer pricing study that includes:

• A FAR analysis
• A detailed risk assessment
• A DEMPE analysis
• Appropriate transfer pricing method selection
• Economic benchmarking

It may be possible to support a lower markup, a higher markup, or even a different transfer pricing methodology, depending on the taxpayer's specific functional profile.

The arm's-length principle requires an analysis of the underlying business reality, not the mechanical application of percentages appearing in individual tax rulings.
 

TNMM Was Approved, But Not Mandated

Under the ruling, the Israeli Tax Authority approved the use of TNMM together with a Mark-Up on Total Costs profitability indicator.

For many limited-risk R&D service providers, TNMM remains a widely accepted method under the OECD Transfer Pricing Guidelines.

However, the ruling should not be interpreted as requiring TNMM in every case.
Method selection remains dependent upon:

• Functional profile
• Risk allocation
• Availability of reliable comparables
• Nature of the controlled transaction
• Ownership and control of intangible assets

In some circumstances, other methods, including Profit Split methodologies, may still be more appropriate.
 

Why the Ruling Increases Rather Than Reduces the Importance of Transfer Pricing Documentation

One of the most significant lessons from Tax Ruling 5007/26 is that high-quality transfer pricing documentation remains essential.

Indeed, the ruling appears to be grounded in precisely the same factors normally analyzed in a transfer pricing study:

• Functional profile
• Industry dynamics
• Economic environment
• Scale of operations
• Nature and complexity of the R&D activities
• Ownership and control of intellectual property
• DEMPE functions

Rather than replacing transfer pricing documentation, the ruling highlights its importance.
 

Tax Audits Do Not Disappear After a Tax Ruling

Even where a taxpayer obtains a tax ruling, the Israeli Tax Authority may continue to monitor whether the factual assumptions underlying the ruling remain accurate.

Questions may include:

• Has risk control remained outside Israel?
• Are strategic decisions still made outside Israel?
• Does the Israeli entity continue to operate as a limited-risk service provider?
• Have DEMPE functions shifted to Israel?
• Have key executives or decision-makers relocated to Israel?

Material changes in facts may justify a reassessment of the transfer pricing model and profit allocation.
 

The Most Important Facts May Not Have Been Published

Perhaps one of the most interesting aspects of the ruling is the statement that additional conditions and limitations exist but were not disclosed publicly.

This means that taxpayers do not have access to the complete factual and legal framework reviewed by the Israeli Tax Authority.

Consequently, comparisons between another taxpayer's circumstances and the ruling should be approached with caution.

Relying solely on the published summary may lead to incomplete conclusions.
 

The Interaction Between Tax Ruling 5007/26 and Israeli Income Tax Circular 8/2025

The ruling should also be considered alongside Israeli Income Tax Circular 8/2025, which seeks to provide additional certainty regarding transfer pricing arrangements for Israeli R&D centers.

For many multinational groups, a practical approach may involve:

Option 1: Preparing a comprehensive transfer pricing study and maintaining it for potential audit purposes.

Option 2: Preparing a comprehensive transfer pricing study and submitting it with the annual Israeli tax return under the framework provided by Circular 8/2025.

Option 3: Using a transfer pricing study as the basis for seeking an advance tax ruling from the Israeli Tax Authority.

In all three scenarios, the transfer pricing analysis remains the foundation.

Practical Implications for Multinational Technology Companies

Companies operating Israeli R&D centers should review:

• Their transfer pricing model
• Intercompany agreements
• FAR analysis
• DEMPE analysis
• Benchmarking studies
• Cost-plus support
• Governance and decision-making structures;
• Intellectual property ownership and control arrangements.

Assuming that a 13% markup automatically applies to every Israeli R&D center can create unnecessary transfer pricing risks, including:

• Double taxation
• Excess taxation in Israel
• Inconsistencies with foreign transfer pricing policies
• Transfer pricing audit exposure
• Challenges by foreign tax authorities

Conclusion

Tax Ruling 5007/26 is undoubtedly an important development in Israeli transfer pricing.

However, its significance is often misunderstood.

The ruling does not establish a universal 13% Net Cost Plus standard for Israeli R&D centers. If anything, it reinforces the opposite principle: transfer pricing outcomes remain determined by facts, functions, assets, risks, DEMPE activities, and economic support.

For multinational technology groups, the real lesson from Tax Ruling 5007/26 is not that 13% has become the new standard.

The real lesson is that a defensible transfer pricing position still begins with a robust, fact-based transfer pricing analysis.